Oprozomib

Generic Name: Oprozomib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₂N_₄O_₇S

CAS Number: 935888-69-0

Unique Ingredient Identifier: MZ37792Y8J

Background: Oprozomib has been used in trials studying the treatment of Solid Tumors, Multiple Myeloma, Waldenstrom Macroglobulinemia, Advanced Hepatocellular Carcinoma, and Advanced Non-Central Nervous System (CNS) Malignancies.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

Phase 1

Terminated

Conditions: Advanced Non-Central Nervous System (CNS) Malignancies

Interventions: Drug: Oprozomib
Drug: Midazolam

First Posted Date: 2014-09-18

Last Posted Date: 2021-02-21

Lead Sponsor: Amgen

Target Recruit Count: 43

Registration Number: NCT02244112

Locations: 🇺🇸
Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States

and more 4 locations

Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Phase 1

Withdrawn

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Drug: Oprozomib
Drug: Sorafenib

First Posted Date: 2014-08-28

Last Posted Date: 2017-05-02

Lead Sponsor: Amgen

Registration Number: NCT02227914

Locations: 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Lahey Hospital & Medical Center, Burlington, California, United States
🇺🇸
The Ohio State University, Martha Morehouse Medical Plaza, Columbus, Ohio, United States

and more 3 locations

A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Oprozomib
Drug: Melphalan
Drug: Prednisone

First Posted Date: 2014-02-27

Last Posted Date: 2017-05-02

Lead Sponsor: Amgen

Target Recruit Count: 9

Registration Number: NCT02072863

Locations: 🇮🇹
Hospital City of Health and Science of Turin, Hematology 1 Division, Turin, Italy
🇮🇹
Ospedale Oncologico Regionale, Rionero in Vulture, Potenza, Italy
🇳🇱
Erasmus MC, Department of Hematology, Rotterdam, Netherlands

and more 5 locations

A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Oprozomib
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2013-12-03

Last Posted Date: 2021-04-27

Lead Sponsor: Amgen

Target Recruit Count: 33

Registration Number: NCT01999335

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
James R. Berenson, MD, Inc., West Hollywood, California, United States
🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States

and more 14 locations

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Oprozomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Cyclophosphamide

First Posted Date: 2013-06-20

Last Posted Date: 2022-11-14

Lead Sponsor: Amgen

Target Recruit Count: 22

Registration Number: NCT01881789

Locations: 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
Providence St. Joseph's Hospital, Burbank, California, United States
🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States

and more 11 locations

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Oprozomib
Drug: Dexamethasone

First Posted Date: 2013-04-16

Last Posted Date: 2020-07-13

Lead Sponsor: Amgen

Target Recruit Count: 65

Registration Number: NCT01832727

Locations: 🇫🇷
CHRU, Hopital Huriez - Department of Hematology, Lille CEDEX, France
🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇫🇷
CHU Hotel Dieu - Service d'Hematologie Clinique, NANTES Cedex, France

and more 10 locations

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Phase 1

Terminated

Conditions: Multiple Myeloma
Waldenstrom Macroglobulinemia

Interventions: Drug: oprozomib

First Posted Date: 2011-08-15

Last Posted Date: 2022-11-08

Lead Sponsor: Amgen

Target Recruit Count: 210

Registration Number: NCT01416428

Locations: 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Pacific Cancer Care, Salinas, California, United States

and more 15 locations

Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Oprozomib

First Posted Date: 2010-05-24

Last Posted Date: 2017-05-02

Lead Sponsor: Amgen

Target Recruit Count: 44

Registration Number: NCT01129349

Locations: 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸
Oncology Research Associates, Scottsdale, Arizona, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy